Top Page
Prophase Labs
(NASDAQ:PRPH)
Prophase Labs (PRPH) vs. SPDR S&P 500 ETF (SPY)
Prophase Labs Business Overview & Revenue Model
Prophase Labs Earnings Call Summary
Prophase Labs Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.34M | 6.77M | 44.38M | 122.65M | 79.04M | 14.51M |
| Gross Profit | 2.02M | -150.00K | 16.24M | 70.65M | 32.81M | 4.61M |
| EBITDA | -26.18M | -32.34M | -14.83M | 28.73M | 11.39M | -1.49M |
| Net Income | -41.45M | -53.36M | -16.78M | 18.46M | 6.27M | -2.13M |
Balance Sheet | ||||||
| Total Assets | 42.04M | 63.20M | 91.93M | 87.65M | 89.30M | 31.41M |
| Cash, Cash Equivalents and Short-Term Investments | 171.00K | 678.00K | 4.74M | 17.44M | 17.26M | 8.46M |
| Total Debt | 5.54M | 24.57M | 21.38M | 6.96M | 14.90M | 14.72M |
| Total Liabilities | 30.61M | 55.85M | 42.54M | 24.02M | 30.67M | 20.85M |
| Stockholders Equity | 11.44M | 7.35M | 49.38M | 63.63M | 58.63M | 10.56M |
Cash Flow | ||||||
| Free Cash Flow | -6.03M | -18.44M | -14.50M | 24.63M | -17.85M | -4.28M |
| Operating Cash Flow | -6.09M | -17.54M | -11.35M | 28.55M | -13.62M | -2.59M |
| Investing Cash Flow | 783.00K | 2.42M | -1.37M | -2.08M | -19.67M | -1.02M |
| Financing Cash Flow | 8.79M | 14.19M | 5.76M | -26.02M | 35.13M | 9.99M |
Prophase Labs Technical Analysis
Prophase Labs Risk Analysis
Prophase Labs Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $20.77M | ― | ― | ― | ― | ― | |
50 Neutral | $22.70M | ― | -60.76% | ― | -18.05% | 33.87% | |
47 Neutral | $13.31M | ― | -1.98% | ― | 156.93% | 92.75% | |
44 Neutral | $10.25M | ― | -33.13% | ― | -7.80% | 90.17% | |
42 Neutral | $10.60M | ― | -36.94% | ― | 2.17% | 88.34% | |
38 Underperform | $12.82M | ― | -230.73% | ― | -24.10% | 38.17% |
Prophase Labs Corporate Events
On October 9, 2025, ProPhase Labs, Inc. entered into an At-the-Market Sales Agreement with WestPark Capital, Inc., allowing the company to offer and sell shares of its common stock through the agent. This agreement, underpinned by the company’s effective registration statement and related prospectus, provides ProPhase Labs with flexibility in its stock offerings, potentially impacting its market presence and financial strategy. The agreement includes customary provisions and allows for termination by either party, reflecting a strategic move to manage its capital and shareholder interests.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On September 12, 2025, ProPhase Labs entered into a Strategic Advisory and Private Placement Agreement with ThinkEquity LLC to serve as its exclusive strategic advisor, placement agent, and investment banker. The agreement involves a proposed private placement of approximately $6 million in securities, with ThinkEquity receiving compensation in cash and warrants. This strategic move is part of ProPhase Labs’ digital asset treasury strategy, potentially impacting its operations and market positioning by involving significant crypto asset accumulation and board representation rights for ThinkEquity.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On September 9, 2025, ProPhase Labs held a Special Meeting of Stockholders where 63.54% of shares were voted. The stockholders approved several proposals including amendments to equity compensation plans, an increase in authorized shares, a share repurchase program, and changes to the company’s bylaws, indicating strategic adjustments to enhance operational flexibility and shareholder value.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
ProPhase Labs’ recent earnings call painted a picture of both optimism and caution, reflecting a balance between promising future prospects and current financial hurdles. The company is poised for potential growth through strategic initiatives, yet faces challenges with stock performance and financial stability.
On August 27, 2025, ProPhase Labs, Inc. announced the termination of its Common Stock Purchase Agreement with Keystone Capital Partners, LLC, which was initially established on January 29, 2025. This agreement allowed ProPhase Labs to sell shares of its common stock to Keystone up to approximately $7.7 million. The termination, effective August 28, 2025, was executed at the company’s discretion without any penalties or fees, and there are no other material relationships between the two entities.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
On August 19, 2025, ProPhase Labs announced the filing of a definitive proxy statement with the SEC and received a ‘no further comments’ letter, indicating the completion of the SEC’s review. The Special Meeting of Shareholders was rescheduled to September 9, 2025, to ensure proper dissemination of proxy materials. The Board recommends shareholders vote ‘FOR’ proposals aimed at strategic growth, including increasing authorized shares and a $15 million share repurchase program. These initiatives are intended to support the company’s crypto treasury strategy, attract major industry partners, and enhance financial flexibility, potentially increasing long-term shareholder value.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
ProPhase Labs Inc. is a diversified company operating in the biotech, genomics, and consumer healthcare sectors, known for its innovative diagnostics and consumer health products. In its latest earnings report, ProPhase Labs announced significant operational and financial improvements for the three and six months ending June 30, 2025, highlighting a strategic shift towards non-dilutive liquidity initiatives and transformational growth catalysts.
ProPhase Labs reported significant financial and operational improvements for the first half of 2025, including a strengthened equity position and reduced liabilities. The company achieved a key U.S. patent for its BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test, positioning it for faster market entry. Additionally, ProPhase streamlined its operations, reduced costs, and improved margins, setting a path for future growth. The company is also exploring a strategic treasury initiative involving digital assets to complement its core businesses.
ProPhase Labs, Inc. announced the resignation of its Chief Operating Officer, Stu Hollenshead, effective July 31, 2025, who will transition to a marketing consultant role. The company is searching for a successor, with interim duties managed by the executive team. Additionally, ProPhase Labs appointed Steven M. Plumb as its fractional Chief Financial Officer on August 6, 2025. Plumb, a seasoned financial executive, will provide operational advice and oversee SEC filings, while CEO Ted Karkus remains the principal financial officer.
On July 29, 2025, ProPhase Labs announced the filing of a Preliminary Proxy Statement with the SEC, aiming to increase authorized shares to 1 billion. This strategic move is intended to attract high-value transactions and industry-leading participants in the crypto treasury space, enhancing the company’s growth potential and flexibility. The Board of Directors has recommended shareholders vote in favor of these proposals at the Special Meeting on August 29, 2025, to strengthen ProPhase Labs’ ability to innovate and create shareholder value.
On July 22, 2025, ProPhase Labs entered into a Securities Purchase Agreement with two investors for a private placement of senior secured convertible notes and warrants, amounting to a principal cash investment of $3,000,000. The transaction is designed to protect long-term shareholder value by preventing excessive dilution and downward price spirals, while also granting investors a first priority security interest in the company’s assets. The net proceeds will be used for working capital, general corporate purposes, and debt repayment. The agreement includes provisions to ensure the company retains control over its assets unless a default occurs.
On July 18, 2025, ProPhase Labs, Inc. held its Annual Meeting of Stockholders where several key decisions were made. The company’s stockholders elected board members, ratified the appointment of independent auditors, approved executive compensation, and decided on the frequency of future advisory votes on executive compensation. Notably, Ms. Carolina Abenante was appointed to the Audit Committee, leading to the company’s compliance with Nasdaq Listing Rules.
On July 23, 2025, ProPhase Labs announced the closing of a $3 million private placement financing with two investors involving senior secured convertible notes and warrants to purchase common stock. The funds will be used for working capital, corporate purposes, and debt repayment, while supporting potential liquidity events and crypto strategies.